Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplier controls may get closer review under possible QSIT change

This article was originally published in The Silver Sheet

Executive Summary

FDA may change its Quality System Inspection Technique (QSIT) to place more emphasis on the auditing of supplier controls, an agency official says. "Purchasing controls is something that right now is very, very timely," Jan Welch, a consumer safety officer in CDRH's Office of Compliance, said at a Global Harmonization Task Force (GHTF) conference Oct. 4 in Washington, D.C. "FDA is giving consideration to revising QSIT, thinking about where purchasing controls might have a more elevated, heightened awareness within QSIT. That's a very, very good thing." Manufacturer problems with outsourcing and supplier controls also is emerging as a hot-button issue for GHTF, which has tasked its Study Group 3 with creating a purchasing control guidance expected to be released in draft form this fall

You may also be interested in...

COVID-19 Lockdown: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.

Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning

Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts